1. Drug–target residence time and its implications for lead optimization;Copeland R.A.;Nat. Rev. Drug Discov.,2006
2. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety;Swinney D.C.;Curr. Top. Med. Chem.,2006
3. Applications of Binding Kinetics to Drug Discovery;Swinney D.C.;Pharm. Med.,2012
4. The drug‐target residence time model: a 10‐year retrospective;Copeland R.A.;Nat. Rev. Drug Discov.,2016
5. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases;Agafonov R.V.;Nat. Struct. Mol. Biol.,2014